NeoStem Names Distinguished UCLA Pathologist Dr. Richard Gatti to Advisory Board
NeoStem, Inc. (OTCBB:NEOI), the first company to specialize in the collection, processing and storage of stem cells from healthy adult donors for personal use in times of critical medical need, has announced that Richard Gatti, M.D., a professor at the University of California, Los Angeles (UCLA) and renowned Pathologist at the UCLA Medical Center, has joined the Company’s Advisory Board. Dr. Gatti was one of the early pioneers of bone marrow transplantation, among the earliest known forms of adult stem cell therapeutics, for immunodeficiency in the late sixties.
As a member of the Advisory Board, Dr. Gatti will help guide NeoStem’s programs as the Company moves to develop a nationwide health-industry network to capitalize on the predicted $8.5 billion stem cell therapeutics industry. Dr. Gatti’s academic and industry contacts are extensive both nationally and internationally and he is a strong proponent of adult stem cell therapies.
“Dr. Gatti’s distinguished work at UCLA will provide key validation as we move to expand our services in Los Angeles and in the west coast region,” said Robin Smith, M.D., Chief Executive Officer of NeoStem. “We are very pleased to welcome him as a strong addition to our Advisory Board. We look forward to his guidance and perspective that only leading scientists and physicians like Dr. Gatti can provide.”
Dr. Gatti is also a leading authority in the field of gene therapeutics and has authored or co-authored hundreds of papers related to the molecular identification and treatment of genetic disorders. He has worked for many years to help find a cure for Ataxia-Telangiectasia, a progressive neurological disorder of childhood, associated with increased cancer risk, immunodeficiency, radiosensitivity, and cell cycle defects.
“I believe that NeoStem’s pioneering stem cell-based services are lighting the way to what may very well become the next great revolution in medicine,” said Dr. Gatti. “I look forward to working with the other distinguished members of the Company’s Advisory Board to provide the guidance they need to realize their forward-thinking vision.”
NeoStem’s visionary senior management, non-capital intensive business model and proprietary processes are making an immediate impact in what many believe to be the “next big thing in consumer health marketing.” The Company has termed this paradigm shift in the medical industry as “bio-insurance,” which empowers health-conscious adults to have their own (autologous) stem cells collected and banked to ensure prompt access for therapeutic use in times of critical medical need.
About NeoStem, Inc
NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need.
The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem cells — providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.
Independent market researchers estimate that stem cell therapy sales in the United States are projected to reach more than $700 million by 2010 and $8.5 billion by 2016 based on therapies under development. Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem’s methods. As the nation’s population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the fast-growing national trend toward personal “bio-insurance.”
The Company’s non-capital intensive business plan is a service model that is completely scalable and can be quickly implemented thus minimizing risk levels ordinarily related to most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem has begun opening a nationwide network of adult stem cell collection facilities, to be processed and stored by the Company. Its stem cell collection systems will be located in existing physician offices and medical facilities, where the procedures and care can be administered by trusted personal doctors and medical professionals.
For more information, please visit: www.neostem.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/neostem/. To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/neostem/quote.html. To view an investor fact sheet about the company, visit http://www.trilogy-capital.com/tcp/neostem/factsheet.html.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. (“the Company”) to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company’s business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company’s ability to enter the adult stem cell arena and future operating results are dependent upon many factors, including but not limited to (i) the Company’s ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company’s ability to build the management and human resources and infrastructure necessary to support the growth of its business and obtain appropriate state licenses; (iii) competitive factors and developments beyond the Company’s control; (iv) scientific and medical developments beyond the Company’s control and (v) other risk factors discussed in the Company’s periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under “Search for Company Filings.”
Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. (“CFSG1″) provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem’s common stock. Independent of CFSG1′s receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit www.cfsg1.com.